StreetInsider.com News Articles

The Precision Peptide Company Becomes Strategic Sponsor of Championing Mental Health 3 Boxing Event

Tue, 22 Sep 2026 07:00:00 -0400

Highlights

BPC brand featured ringside at a live professional boxing event on September 26, 2026.¹
Broadcast on UFC Fight Pass, which according to UFC is available in more than 200 countries and territories.²
The prior CMH event was headlined by a WBC Cruiserweight World Championship bout.³,⁴
Positions BPC in front of its core audience: combat sports athletes and fans focused on recovery and performance.
Extends BPC's combat sports strategy following its exclusive marketing agreement with MMA.INC announced on May 12, 2026.

Vancouver, British Columbia--(Newsfile Corp. - September 22, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness

The Precision Peptide Company Becomes Strategic Sponsor of Championing Mental Health 3 Boxing Event

Tue, 22 Sep 2026 07:00:00 -0400

Highlights

BPC brand featured ringside at a live professional boxing event on September 26, 2026.¹
Broadcast on UFC Fight Pass, which according to UFC is available in more than 200 countries and territories.²
The prior CMH event was headlined by a WBC Cruiserweight World Championship bout.³,⁴
Positions BPC in front of its core audience: combat sports athletes and fans focused on recovery and performance.
Extends BPC's combat sports strategy following its exclusive marketing agreement with MMA.INC announced on May 12, 2026.

Vancouver, British Columbia--(Newsfile Corp. - September 22, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness

The Precision Peptide Company Becomes Strategic Sponsor of Championing Mental Health 3 Boxing Event

Tue, 22 Sep 2026 07:00:00 -0400

Highlights

BPC brand featured ringside at a live professional boxing event on September 26, 2026.¹
Broadcast on UFC Fight Pass, which according to UFC is available in more than 200 countries and territories.²
The prior CMH event was headlined by a WBC Cruiserweight World Championship bout.³,⁴
Positions BPC in front of its core audience: combat sports athletes and fans focused on recovery and performance.
Extends BPC's combat sports strategy following its exclusive marketing agreement with MMA.INC announced on May 12, 2026.

Vancouver, British Columbia--(Newsfile Corp. - September 22, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness

The Precision Peptide Company Becomes Strategic Sponsor of Championing Mental Health 3 Boxing Event

Tue, 22 Sep 2026 07:00:00 -0400

Highlights

BPC brand featured ringside at a live professional boxing event on September 26, 2026.¹
Broadcast on UFC Fight Pass, which according to UFC is available in more than 200 countries and territories.²
The prior CMH event was headlined by a WBC Cruiserweight World Championship bout.³,⁴
Positions BPC in front of its core audience: combat sports athletes and fans focused on recovery and performance.
Extends BPC's combat sports strategy following its exclusive marketing agreement with MMA.INC announced on May 12, 2026.

Vancouver, British Columbia--(Newsfile Corp. - September 22, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness

The Precision Peptide Company Announces Sponsorship of Boulderthon, Boulder Colorado's Marathon Weekend

Tue, 15 Sep 2026 07:00:00 -0400

Company to Showcase Its U.S.-Made Peptide Products at a Booth During Race Weekend, September 27, 2026

Highlights

Boulderthon 2026 takes place on Sunday, September 27, 2026, in Boulder, Colorado, finishing on the historic Pearl Street Mall.¹
According to race organizers, the event welcomed over 15,600 runners in 2025, a 56 percent increase over the prior year, drawing runners from all 50 states and 22 countries.³
Boulderthon is a Boston Marathon Qualifying, USATF Sanctioned event named Top 10 in America by USA Today and among the Best Fall Marathons by Runner's World.^{1, 3}
BPC plans an on-site booth at the outdoor Boulderthon Expo, which organizers report

The Precision Peptide Company Announces Sponsorship of Boulderthon, Boulder Colorado's Marathon Weekend

Tue, 15 Sep 2026 07:00:00 -0400

Company to Showcase Its U.S.-Made Peptide Products at a Booth During Race Weekend, September 27, 2026

Highlights

Boulderthon 2026 takes place on Sunday, September 27, 2026, in Boulder, Colorado, finishing on the historic Pearl Street Mall.¹
According to race organizers, the event welcomed over 15,600 runners in 2025, a 56 percent increase over the prior year, drawing runners from all 50 states and 22 countries.³
Boulderthon is a Boston Marathon Qualifying, USATF Sanctioned event named Top 10 in America by USA Today and among the Best Fall Marathons by Runner's World.^{1, 3}
BPC plans an on-site booth at the outdoor Boulderthon Expo, which organizers report

The Precision Peptide Company Announces Sponsorship of Boulderthon, Boulder Colorado's Marathon Weekend

Tue, 15 Sep 2026 07:00:00 -0400

Company to Showcase Its U.S.-Made Peptide Products at a Booth During Race Weekend, September 27, 2026

Highlights

Boulderthon 2026 takes place on Sunday, September 27, 2026, in Boulder, Colorado, finishing on the historic Pearl Street Mall.¹
According to race organizers, the event welcomed over 15,600 runners in 2025, a 56 percent increase over the prior year, drawing runners from all 50 states and 22 countries.³
Boulderthon is a Boston Marathon Qualifying, USATF Sanctioned event named Top 10 in America by USA Today and among the Best Fall Marathons by Runner's World.^{1, 3}
BPC plans an on-site booth at the outdoor Boulderthon Expo, which organizers report

The Precision Peptide Company Announces Sponsorship of Boulderthon, Boulder Colorado's Marathon Weekend

Tue, 15 Sep 2026 07:00:00 -0400

Company to Showcase Its U.S.-Made Peptide Products at a Booth During Race Weekend, September 27, 2026

Highlights

Boulderthon 2026 takes place on Sunday, September 27, 2026, in Boulder, Colorado, finishing on the historic Pearl Street Mall.¹
According to race organizers, the event welcomed over 15,600 runners in 2025, a 56 percent increase over the prior year, drawing runners from all 50 states and 22 countries.³
Boulderthon is a Boston Marathon Qualifying, USATF Sanctioned event named Top 10 in America by USA Today and among the Best Fall Marathons by Runner's World.^{1, 3}
BPC plans an on-site booth at the outdoor Boulderthon Expo, which organizers report

The Precision Peptide Company Announces Digital Marketing and Advertising Services Agreements

Thu, 10 Sep 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it has entered into agreements with (i) Senergy Communications Capital Inc. ("Senergy") and (ii) 1000903966 Ontario Inc., d.b.a. Komcore Capital ("Komcore"), to provide certain digital marketing and advertising services to the Company.

Senergy

The Company has entered into a digital marketing services agreement with Senergy (the "Senergy Agreement") to provide certain digital marketing and similar services to the Company. Pursuant to the Senergy Agreement, Senergy shall provide services including onboarding, setting up required ad accounts and

The Precision Peptide Company Announces Digital Marketing and Advertising Services Agreements

Thu, 10 Sep 2026 07:00:00 -0400

Senergy

The Precision Peptide Company Announces Digital Marketing and Advertising Services Agreements

Thu, 10 Sep 2026 07:00:00 -0400

Senergy

The Precision Peptide Company Announces Digital Marketing and Advertising Services Agreements

Thu, 10 Sep 2026 07:00:00 -0400

Senergy

The Precision Peptide Company Advances Thymosin Alpha-1 Patch into Formal U.S. Testing

Tue, 08 Sep 2026 07:00:00 -0400

Second transdermal peptide patch expands the Company's growing portfolio across oral, topical and needle-free wellness formats

Highlights

U.S. testing now underway for the Thymosin Alpha-1 transdermal patch
Completion of the testing program is targeted for Q3/Q4 of 2026
Second transdermal peptide product to advance following BPC-157
US$56.06 billion global peptide therapeutics market in 2026, projected to reach US$87.21 billion by 2035¹
July 2026 FDA review highlights U.S. regulatory attention surrounding peptides²
Potential first-to-market, needle-free TA1 format addresses a traditional delivery gap

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company

The Precision Peptide Company Advances Thymosin Alpha-1 Patch into Formal U.S. Testing

Tue, 08 Sep 2026 07:00:00 -0400

Second transdermal peptide patch expands the Company's growing portfolio across oral, topical and needle-free wellness formats

Highlights

U.S. testing now underway for the Thymosin Alpha-1 transdermal patch
Completion of the testing program is targeted for Q3/Q4 of 2026
Second transdermal peptide product to advance following BPC-157
US$56.06 billion global peptide therapeutics market in 2026, projected to reach US$87.21 billion by 2035¹
July 2026 FDA review highlights U.S. regulatory attention surrounding peptides²
Potential first-to-market, needle-free TA1 format addresses a traditional delivery gap

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company

The Precision Peptide Company Advances Thymosin Alpha-1 Patch into Formal U.S. Testing

Tue, 08 Sep 2026 07:00:00 -0400

Second transdermal peptide patch expands the Company's growing portfolio across oral, topical and needle-free wellness formats

Highlights

U.S. testing now underway for the Thymosin Alpha-1 transdermal patch
Completion of the testing program is targeted for Q3/Q4 of 2026
Second transdermal peptide product to advance following BPC-157
US$56.06 billion global peptide therapeutics market in 2026, projected to reach US$87.21 billion by 2035¹
July 2026 FDA review highlights U.S. regulatory attention surrounding peptides²
Potential first-to-market, needle-free TA1 format addresses a traditional delivery gap

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company

The Precision Peptide Company Advances Thymosin Alpha-1 Patch into Formal U.S. Testing

Tue, 08 Sep 2026 07:00:00 -0400

Second transdermal peptide patch expands the Company's growing portfolio across oral, topical and needle-free wellness formats

Highlights

U.S. testing now underway for the Thymosin Alpha-1 transdermal patch
Completion of the testing program is targeted for Q3/Q4 of 2026
Second transdermal peptide product to advance following BPC-157
US$56.06 billion global peptide therapeutics market in 2026, projected to reach US$87.21 billion by 2035¹
July 2026 FDA review highlights U.S. regulatory attention surrounding peptides²
Potential first-to-market, needle-free TA1 format addresses a traditional delivery gap

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company

The Precision Peptide Company Announces Grants of RSUs and Stock Options

Fri, 04 Sep 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 4, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company") announces that on July 31, 2026, it has authorized the grant of restricted share units (the "RSUs") and incentive stock options (the "Options") pursuant to the Company's omnibus share incentive plan (the "Plan").

The Company has granted 150,000 RSUs and 200,000 Options to a certain consultant of the Company. Each Option entitles the holder to acquire one common share of the Company ("Share") at an exercise price of $0.50 per Share for a period of ten (10) years from the date

The Precision Peptide Company Announces Grants of RSUs and Stock Options

Fri, 04 Sep 2026 17:00:00 -0400

The Precision Peptide Company Announces Grants of RSUs and Stock Options

Fri, 04 Sep 2026 17:00:00 -0400

The Precision Peptide Company Announces Grants of RSUs and Stock Options

Fri, 04 Sep 2026 17:00:00 -0400

MMA.INC partners with Precision Peptide in 50/50 revenue share deal

Tue, 12 May 2026 08:31:50 -0400

Mixed Martial Arts Group Limited (NYSE American: MMA) announced an exclusive marketing partnership with The Precision Peptide Company Inc. (CSE: BPC; OTCQB: PNGAF) to sell peptide recovery products across its global combat sports network.

Under the agreement, MMA.INC will receive 50% of net revenue from sales generated through its platform during the first twelve months, followed by 25% of net revenue for the remainder of the partnership term. The company will market Precision's U.S.-manufactured and third-party tested peptide products through its ecosystem of platforms including TrainAlta, BJJLink, and MixedMartialArts.com.

The partnership can be terminated by either party with 30 days written notice.

MMA.INC partners with Precision Peptide in 50/50 revenue share deal

Tue, 12 May 2026 08:31:50 -0400

The partnership can be terminated by either party with 30 days written notice.

MMA.INC partners with Precision Peptide in 50/50 revenue share deal

Tue, 12 May 2026 08:31:50 -0400

The partnership can be terminated by either party with 30 days written notice.

MMA.INC (NYSE American: MMA) Enters Exclusive 50/50 Revenue Share Peptide Partnership with Precision Peptide (CSE: BPC)

Tue, 12 May 2026 08:30:00 -0400

Exclusive agreement gives MMA.INC direct participation in sales of U.S. manufactured, third party tested peptide recovery products across its global combat sports ecosystem

Highlights

MMA.INC enters high-growth peptide therapeutics and recovery market focused on the global martial arts community
Exclusive partnership with Precision Peptide Company Inc, a premium U.S.-manufactured peptide company listed on the CSE
MMA.INC to participate directly in revenue generated across its global customer base
Partnership provides MMA.INC a 50/50 share of MMA-generated net revenue in year 1 and 25% of net revenue for the remainder of the Term

New York,

MMA.INC (NYSE American: MMA) Enters Exclusive 50/50 Revenue Share Peptide Partnership with Precision Peptide (CSE: BPC)

Tue, 12 May 2026 08:30:00 -0400

Exclusive agreement gives MMA.INC direct participation in sales of U.S. manufactured, third party tested peptide recovery products across its global combat sports ecosystem

Highlights

MMA.INC enters high-growth peptide therapeutics and recovery market focused on the global martial arts community
Exclusive partnership with Precision Peptide Company Inc, a premium U.S.-manufactured peptide company listed on the CSE
MMA.INC to participate directly in revenue generated across its global customer base
Partnership provides MMA.INC a 50/50 share of MMA-generated net revenue in year 1 and 25% of net revenue for the remainder of the Term

New York,